Company Filing History:
Years Active: 1999-2004
Title: Claude Wildmann: Innovator in Cancer Research
Introduction
Claude Wildmann is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly in the development of methods for identifying and treating individuals with cellular abnormalities. With a total of 5 patents to his name, Wildmann's work is at the forefront of innovative medical solutions.
Latest Patents
Wildmann's latest patents include a method for identifying individuals suffering from a cellular abnormality, specifically those whose abnormal cells present complexes of HLA-CW 1601/MAGE-1 derived peptides. This method involves peptides that bind to HLA-Cw*1601 molecules and stimulate the proliferation of cytolytic T cells. Additionally, he has developed a method for treating subjects using BAGE tumor rejection antigen precursors, which are crucial for various diagnostic and therapeutic applications.
Career Highlights
Claude Wildmann is associated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research. His innovative approaches have the potential to significantly impact cancer treatment and patient outcomes.
Collaborations
Wildmann has collaborated with notable colleagues such as Thierry R Boon-Falleur and Pierre Van Der Bruggen, enhancing the scope and depth of his research endeavors.
Conclusion
Claude Wildmann's contributions to cancer research through his patents and collaborative efforts highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical science and patient care.